rs61735621
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 1P and 8B. PP2BP4_StrongBS2
The ENST00000257290.10(PDGFRA):c.1280C>T(p.Ser427Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000998 in 1,614,002 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S427P) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000257290.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PDGFRA | NM_006206.6 | c.1280C>T | p.Ser427Leu | missense_variant | 9/23 | ENST00000257290.10 | NP_006197.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PDGFRA | ENST00000257290.10 | c.1280C>T | p.Ser427Leu | missense_variant | 9/23 | 1 | NM_006206.6 | ENSP00000257290 | P1 | |
PDGFRA | ENST00000509092.5 | n.1098C>T | non_coding_transcript_exon_variant | 8/15 | 1 | |||||
PDGFRA | ENST00000509490.5 | c.1280C>T | p.Ser427Leu | missense_variant, NMD_transcript_variant | 9/18 | 1 | ENSP00000424218 |
Frequencies
GnomAD3 genomes AF: 0.000533 AC: 81AN: 152070Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000159 AC: 40AN: 251334Hom.: 0 AF XY: 0.000118 AC XY: 16AN XY: 135838
GnomAD4 exome AF: 0.0000547 AC: 80AN: 1461814Hom.: 0 Cov.: 32 AF XY: 0.0000371 AC XY: 27AN XY: 727222
GnomAD4 genome AF: 0.000532 AC: 81AN: 152188Hom.: 0 Cov.: 31 AF XY: 0.000551 AC XY: 41AN XY: 74392
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Jun 22, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 29, 2019 | The p.S427L variant (also known as c.1280C>T), located in coding exon 8 of the PDGFRA gene, results from a C to T substitution at nucleotide position 1280. The serine at codon 427 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Idiopathic hypereosinophilic syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 08, 2020 | - - |
Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Jul 12, 2022 | The PDGFRA c.1280C>T (p.Ser427Leu) missense change has a maximum subpopulation frequency of 0.21% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL is inconclusive about a pathogenic or benign effect of this variant on protein function, and to our knowledge functional studies have not been performed. To our knowledge, this variant has not been reported in individuals with PDGFRA-associated tumors. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 21, 2022 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
PDGFRA-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 21, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Gastrointestinal stromal tumor Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at